Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Emerich

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
Journal of Applied Genetics|October 31, 2009
Loss of heterozygosity at BRCA1/2 loci in hereditary and sporadic ovarian cancersI Brozek, K Ochman, J Debniak, et al.
Cancer Immunology, Immunotherapy : CII|November 30, 2006
Mannan-binding lectin (MBL) in women with tumours of the reproductive systemA St Swierzko, K Florczak, M Cedzyński, et al.
The Journal of Rheumatology|August 18, 1999
Use of ELISA to measure antinuclear antibodies in children with juvenile rheumatoid arthritisP T Fawcett, C D Rose, K M Gibney, et al.
Fundamental & Clinical Pharmacology|January 1, 1997
Pharmacological characterization of the contractile effects of galanin (1-29)-NH2, galantide and galanin (1-14)-(alpha-aminobutyric acid8)scyliorhinin-I in the rat gastric fundusR Korolkiewicz, W Sliwiński, Z Konstański, et al.
European Journal of Gynaecological Oncology|June 2, 2009
Microsatellite instability and HPV genotype in Polish women with cervical cancerM F D Baay, M Nakonieczny, I Wozniak, et al.
European Journal of Gynaecological Oncology|October 31, 2007
Significance of hypoxia in uterine cervical cancer. Multicentre studyJ Markowska, J P Grabowski, K Tomaszewska, et al.
European Journal of Gynaecological Oncology|June 8, 2000
Factors influencing period of time between negative second-look laparotomy and ovarian carcinoma recurrence. Multicenter study in PolandJ Markowska, J Wilkoszarska, J Emerich, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 6, 2003
Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapyM J Piccart, A Floquet, G Scarfone, et al.
Gynecologic Oncology|November 25, 1998
Cytogenetics of uterine sarcomas: presentation of eight new cases and review of the literatureM Iliszko, N Mandahl, K Mrózek, et al.
British Journal of Cancer|November 17, 2004
TP53 status determines clinical significance of ERBB2 expression in ovarian cancerJ Kupryjańczyk, R Madry, J Plisiecka-Hałasa, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Journal of Applied Genetics|October 31, 2009
Loss of heterozygosity at BRCA1/2 loci in hereditary and sporadic ovarian cancersI Brozek, K Ochman, J Debniak, et al.
Cancer Immunology, Immunotherapy : CII|November 30, 2006
Mannan-binding lectin (MBL) in women with tumours of the reproductive systemA St Swierzko, K Florczak, M Cedzyński, et al.
The Journal of Rheumatology|August 18, 1999
Use of ELISA to measure antinuclear antibodies in children with juvenile rheumatoid arthritisP T Fawcett, C D Rose, K M Gibney, et al.
Fundamental & Clinical Pharmacology|January 1, 1997
Pharmacological characterization of the contractile effects of galanin (1-29)-NH2, galantide and galanin (1-14)-(alpha-aminobutyric acid8)scyliorhinin-I in the rat gastric fundusR Korolkiewicz, W Sliwiński, Z Konstański, et al.
European Journal of Gynaecological Oncology|June 2, 2009
Microsatellite instability and HPV genotype in Polish women with cervical cancerM F D Baay, M Nakonieczny, I Wozniak, et al.
European Journal of Gynaecological Oncology|October 31, 2007
Significance of hypoxia in uterine cervical cancer. Multicentre studyJ Markowska, J P Grabowski, K Tomaszewska, et al.
European Journal of Gynaecological Oncology|June 8, 2000
Factors influencing period of time between negative second-look laparotomy and ovarian carcinoma recurrence. Multicenter study in PolandJ Markowska, J Wilkoszarska, J Emerich, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 6, 2003
Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapyM J Piccart, A Floquet, G Scarfone, et al.
Gynecologic Oncology|November 25, 1998
Cytogenetics of uterine sarcomas: presentation of eight new cases and review of the literatureM Iliszko, N Mandahl, K Mrózek, et al.
British Journal of Cancer|November 17, 2004
TP53 status determines clinical significance of ERBB2 expression in ovarian cancerJ Kupryjańczyk, R Madry, J Plisiecka-Hałasa, et al.
Pageof 8